QUOTE AND NEWS
Stock Blog Hub  3 hrs ago  Comment 
Acorda Therapeutics (ACOR) is one of the more interesting biotechnology companies under our coverage. The company's key pipeline drug, Fampridine-SR, is currently under U.S. FDA review, with a decision expected in late January 2010. Outside...
StreetInsider.com  Nov 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Acorda+Thera+%28ACOR%29+Posts+Q3+Loss+of+%240.51%2C+8c+Better+than+Estimates/5067530.html for the full story.
Business Wire  Nov 3  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter of 2009. “The positive vote from the FDA Advisory Committee was an important step toward making Fampridine-SR available to people with multiple
Business Wire  Oct 27  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today that it will host a conference call and live audio webcast to report its financial results for the third quarter 2009 on Tuesday, November 3, 2009 at 8:30 a.m. ET before the U.S. financial
Business Wire  Oct 22  Comment 
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010. The original
Wall Street Journal  Oct 16  Comment 
Small-capitalization stocks closed near flat Thursday, as a jump in the energy sector on rising oil prices was largely offset by declines across technology and financial shares.
Wall Street Journal  Oct 15  Comment 
Small-capitalization stocks closed near flat Thursday, as a jump in the energy sector on rising oil prices was largely offset by declines across technology and financial shares.
Motley Fool  Oct 15  Comment 
FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.
StreetInsider.com  Oct 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Merriman+Curhan+Ford+Upgrades+Acorda+Therapeutics+%28ACOR%29+to+Buy%3B+FDA+in+Coach%27s+Corner/5018494.html for the full story.
StreetInsider.com  Oct 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Baird+Upgrades+Acorda+Therapeutics+%28ACOR%29+to+Outperform%3B+Significant+Opportunity+/5018455.html for the full story.
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS
ACOR AT A GLANCE
 
 
 
 
 
 
 
 

Acorda Therapeutics is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Core technologies developed by Acorda for SCI and MS have potentially broad applicability for other neurologic conditions. Focusing on these conditions provides insight into chronic and acute CNS conditions. The company has one major product currently approved for sale with Zanaflex and one major candidate in late-stage clinical trials with Fampridine-SR. Zanaflex is a short-acting drug approved for the management of spasticity. Fampridine-SR is being developed in human clinical trials for both MS and spinal cord injury. Acorda, located in Hawthorne, NY, employs roughly 125 professionals. The company was founded in 1995 and completed its initial public offering (IPO) in February 2006 with the sale of 5.5 million common shares at $6.00. An over-allotment sale of 0.575 million shares followed in March 2006, along with a private placement of 3.2 million shares in October 2006 and another 4.2 million shares offered to the public and over-allotment in June 2007.



References

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki